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CHAPTER 3
Supplemental Table A1: Multiple logistic regression model for metabolic syndrome at follow-up 
with SNP rs523349 (V89L) and known confounding factors as predictor (n = 164, patients using 
testosterone supplementation excluded)
  OR 95% CI P-value
SNP rs523349 2.56 1.02 - 6.40 .044
Age at follow-up 1.04 0.98 - 1.10 .234
Follow-up duration 1.02 0.93 - 1.12 .691
Body Mass Index* 1.54 1.30 - 1.82 .000
Testosterone** 0.99 0.91 - 1.08 .851
*Body mass index (BMI) was added in this model because of the association between testosterone and BMI. **Testosterone 
were added in this model because of the association between testosterone and metabolic syndrome. SNP: single nucleotide 
polymorphism; OR: odds ratio; CI: confidence interval.
Supplemental Table A2: Multiple logistic regression model for metabolic syndrome at follow-up 
with SNP rs523349 (V89L) and known confounding factors as predictor
  OR 95% CI P-value
SNP rs523349 2.13 1.03 - 4.37 .040
Age at follow-up 1.05 1.00 - 1.10 .027
Follow-up duration 1.04 0.96 - 1.13 .338
SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval.
Supplemental Table B: Multiple linear regression model for intima-media thickness at follow-up 
with SNP rs523349 (V89L) and known confounding factors as predictor
  B Std. Error β P-value
Constant .316 .044 .000
SNP rs523349 .037 .017 .150 .037
Age at follow-up .006 .001 .440 .000
Follow-up duration .000 .002 -.012 .875
Std. Error: standard error; SNP: single nucleotide polymorphism
Supplemental Table C: Multiple linear regression model for albumin excretion in 24-h urine at 
follow-up (log-transformed) with SNP rs523349 (V89L) and known confounding factors as predictor
  B Std. Error β P-value
Constant -.514 .665 .441
SNP rs523349 .539 .261 .157 .040
Age at follow-up .019 .017 .093 .275
Follow-up duration .040 .033 .103 .225
Std. Error: standard error; SNP: single nucleotide polymorphism
S
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CHAPTER 4
Supplemental Fig. A: Von Willebrand Factor (vWF) and Factor VIII (FVIII) levels of breast cancer 
patients of both groups at all time-points. Dots represent individual measurements. Grey bar 
represents reference range of vWF and FVIII. PE: physical exercise.


































Supplemental Fig. A: Overall survival of testicular cancer patients treated with bleomycin-cisplatin 
combination chemotherapy according to HFE C282Y variant status.















Heterozygote HFE C282Y variant (n=28)
supplemental files
S





























Processed on: 2-5-2018 PDF page: 134
134
Supplemental Table A1: Baseline characteristics of the patients with the C282Y variant.
Wild-type (n = 336) Heterozygote for C282Y (n = 28) P-value
Age at start chemotherapy (yr), 
median (range) 27 (16-64) 31 (16-50) 0.489
‡
Stage (Royal Marsden)1, n (%)
II 158 (48.0%) 14 (53.8%)
0.627+III 32 (9.7%) 1 (3.8%)
IV 139 (42.2%) 11 (42.3%)
IGCCCG2, n (%)
Good 160 (52.5%) 11 (42.3%)
0.362+Intermediate 98 (32.1%) 12 (46.2%)
Poor 47 (15.4%) 3 (11.5%)
Metastases
Pulmonary metastases3, n (%) 138 (41.7%) 11 (39.3%) 0.804+
Chemotherapy regimen, n (%)
BEP 257 (76.5%) 22 (78.6%)
0.071†
PVB 43 (12.8%) 1 (3.6%)
PVB/BEP 28 (8.3%) 2 (7.1%)
Other regimens 8 (2.4%) 3 (10.7%)
Chemotherapy dosage
Cumulative dose bleomycine (USP), 
median (range) 270.0 (60-360) 270.0 (90-360) 0.075
‡
Cumulative dose cisplatin (mg/m2), 
median (range)  400.0 (80-1300) 400.0 (300-800) 0.616
‡
Creatinine clearance
CRCL (ml/min), median (range) 122.3 (41 - 225) 128.2 (88-202) 0.341‡
‡ Mann-Whitney U test, + Chi-square test, † Fisher’s exact test. CRCL: Creatinine clearance with Cockcroft-Gault formula; 
IGCCCG: International Germ Cell Consensus Classification Group; BEP: bleomycin - etoposide - cisplatin combination 
chemotherapy; PVB: cisplatin - vinblastine - bleomycin combination chemotherapy; USP: U.S. Pharmacopeia. 1Royal Marsden 
stage missing: wild-type - 7 patients, heterozygote - 2 patients,2 IGCCCG missing: wild-type - 31 patients, H63D variant, 
C282Y variant or both - 2 patients, 3pulmonary metastases missing: wild-type: 5 patients
Supplemental Table A2: Analysis of testicular cancer patients with C282Y variant: occurrence of 
BIP and risk factors for BIP
Wild-type (n = 328) Heterozygote for C282Y (n = 27) P-value
BIP, n (%)** 47 (14.3%) 2 (7.4%) 0.559+
Age at start of chemotherapy (yr), 
median (range) 27 (16-64) 31 (16-50) 0.635
‡
Cumulative dose bleomycin (USP), 
median (range) 270.0 (60-360) 270.0 (90-360) 0.126
‡
CRCL (ml/min), median (range) 122.5 (41 - 225) 129.6 (88-202) 0.314‡
Pulmonary metastases1, n (%) 136 (42.0%) 11 (40.7%) 0.901+
Smokers, current and previous2, 
n (%) 178 (61.6%) 13 (50.0%) 0.352+
Non-smokers2, n (%) 111 (38.4%) 13 (50.0%)
‡ Mann-Whitney U test, + Chi square, ** In 355 of 364 patients information of BIP status was available. BIP: bleomycin-induced 
pulmonary toxicity, CRCL: Creatinine clearance calculated with Cockcroft-Gault formula; USP: U.S. Pharmacopeia.1pulmonary 
metastases missing: wild-type - 4 patients, 2smokers/non-smokers; wild-type - 39 patients, heterozygote - 1 patient
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Supplemental Table B1: Baseline characteristics of the patients with the H63D variant, the C282Y 
variant or both
Wild-type (n = 257) H63D variant, C282Y variant or both (n = 104) P-value
Age at start chemotherapy (yr), 
median (range) 28 (16-64) 28 (16-54) 0.756
‡
 Stage (Royal Marsden)1, n (%)
II 123 (48.6%) 48 (48.5%)
0.616+III 26 (10.3%) 7 (7.1%)
IV 104 (41.1%) 44 (44.4%)
IGCCCG2, n (%)
Good 126 (53.6%) 45 (47.9%)
0.462+Intermediate 78 (33.2%) 32 (34.0%)
Poor 31 (13.2%) 17 (18.1%)
Metastases
Pulmonary metastases3 , n (%) 104 (40.9%) 43 (42.2%) 0.834+
Chemotherapy regimen, n (%)
0.499+BEP 200 (77.8%) 76 (73.1%)
PVB 29 (11.3%) 15 (14.4%)
PVB/BEP 22 (8.6%) 8 (7.7%)
Other regimens 6 (2.3%) 5 (4.8%)
Chemotherapy dosage
Cumulative dose bleomycine (USP), 
median (range) 270 (60-360) 270 (90-360) 0.327
‡
Cumulative dose cisplatin (mg/m2), 
median (range) 400 (80-1300) 400 (300-950) 0.272
‡
Creatinine clearance
CRCL (ml/min), median (range) 121.8 (65.0-225.2) 123.4 (41.0-202.3) 0.918‡
‡ Mann-Whitney U test, + Chi square test.
CRCL: Creatinine clearance with Cockcroft-Gault formula, IGCCCG: International Germ Cell Consensus Classification Group; 
BEP: bleomycin - etoposide - cisplatin combination chemotherapy; PVB: cisplatin - vinblastine - bleomycin combination 
chemotherapy; USP: U.S. Pharmacopeia. 1Royal Marsden stage missing: wild type - 4 patients, H63D variant, C282Y variant 
or both - 5 patients, 2 IGCCCG missing: wild type - 22 patients, H63D variant, C282Y variant or both - 10 patients, 3pulmonary 
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Supplemental Table B2: Combined analysis of testicular cancer patients with the H63D variant, 
the C282Y variant or both: occurrence of BIP and risk factors for BIP.
Wild-type (n = 251) H63D variant, C282Y variant or both (n = 101) P-value
BIP, n (%)** 30 (12.0%) 19 (18.8%) 0.093+
Age at start of chemotherapy (yr), 
median (range)
28 (16-64) 28 (17-55) 0.731‡
Cumulative dose bleomycin (USP), 
median (range) 270 (60-360) 270 (90-360) 0.433
‡
CRCL (ml/min), median (range)  122.5 (65.0-225.2) 123.3 (41.0-202.3) 0.925‡
Pulmonary metastases1, n (%) ( 102 (41.1%) 43 (43.0%) 0.749+
Smokers, current and previous2, 
n (%) 139 ( 62.3%) 51 (56.7%) 0.353
+
Non-smokers2, n (%) 84 (37.7%) 39 ( 43.3%)
‡ Mann-Whitney U test, + Chi square test. ** In 357 of 361 patients information of BIP status was available
BIP: bleomycin-induced pulmonary toxicity, CRCL: Creatinine clearance calculated with Cockcroft-Gault formula; USP: U.S. 
Pharmacopeia. 1pulmonary metastases missing: wild type - 3 patients, heterozygote - 1 patient, 2smokers/non-smokers 
missing: wild type - 28 patients, heterozygote - 11 patients
Supplemental Table C: Combined analysis of testicular cancer patients with the H63D variant, the 
C282Y variant or both: Renal function
Wild-type (n = 255)
H63D variant, C282Y 




Serum creatinine (µmol/l), median 
(range) 86 (54-149) 88 (57-228) 0.551
‡
CRCL (ml/min), median (range) 121.8 (65.0-225.2) 123.4 (41.0-202.3) 0.918‡
Post-chemotherapy
Serum creatinine (µmol/l), median 
(range) 96 (66-876) 94 (67-182) 0.220
‡
CRCL (ml/min), median (range) 106.6 (11.0-204.7) 112.9 (52.9-202.7) 0.079‡
Delta pre- and post-chemotherapy
Delta CRCL pre and post 
chemotherapy, median (range) 12.7 (-53.3-88.9) 9.6 (-34.2-103.0) 0.162
‡
1 year after start of chemotherapy
Serum creatinine (µmol/l), median 
(range) 99 (70-537) 96 (72-156) 0.235
‡
CRCL (ml/min), median (range) 112.1 (20.8 - 185.3) 107.1 (64.7-194.8) 0.921‡
10 years after start of chemotherapy
Serum creatinine (µmol/l), median 
(range) 101 (75-252) 100 (73-33) 0.765
‡
CRCL (ml/min), median (range) 106.3 (39.1-227.1) 101.8 (69.2-175.1) 0.777‡
‡ Mann-Whitney U test.
CRCL: Creatinine clearance calculated with Cockcroft-Gault formula
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